Program Type: New England CEPAC

Multiple Sclerosis: CIS, RRMS, and SPMS

Jan 2023 | Assessment

Interventions of Interest: Monoclonal Antibodies natalizumab (Tysabri®, Biogen) ofatumumab (Kesimpta®, Novartis) ocrelizumab (Ocrevus®, Genentech) rituximab (Rituxan®, Genentech, and biosimilars) ublituximab (TG Therapeutics)  Oral Therapies dimethyl fumarate (Tecfidera®, Biogen, and generics) diroximel fumarate (Vumerity®, Biogen) monomethyl fumarate (Bafiertam®, Banner Life Sciences) fingolimod (Gilenya®, Novartis) ozanimod (Zeposia®, Bristol Myers Squibb) ponesimod (Ponvory®, Janssen) siponimod (Mayzent®, Novartis) teriflunomide […]

Obesity Management

Sep 2022 | Assessment

Interventions of Interest: subcutaneous semaglutide (Wegovy, Novo Nordisk) liraglutide (Saxenda, Novo Nordisk) phentermine/topiramate (Qsymia, Vivus Pharmaceuticals) naltrexone/bupropion (Contrave, Currax Pharma) The independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit compared to lifestyle modification alone; however, at current pricing, semaglutide represents “low” long-term value for money. Semaglutide […]

Beta Thalassemia

Jun 2022 | Assessment

Interventions of Interest: betibeglogene autotemcel (Zynteglo, bluebird bio) The independent appraisal committee unanimously determined that the evidence is adequate to demonstrate that beti-cel provides a net health benefit compared to standard clinical management. Given the high costs of standard care, cost-effectiveness modeling finds beti-cel meets commonly accepted value thresholds at an anticipated price of $2.1 […]

Diabetes: Type 2

Jan 2022 | Assessment

Interventions of Interest: tirzepatide (Mounjaro™, Eli Lilly) Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as an add-on type 2 diabetes therapy; tirzepatide would achieve common thresholds for cost-effectiveness if priced between $5,500 – $5,700 per year.  At the January 20 virtual meeting, ICER’s independent appraisal committee […]

Myasthenia Gravis

Sep 2021 | Assessment

Interventions of Interest: Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) Efgartigimod (Vyvgart™, argenx) The independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a net health benefit when compared to conventional therapy alone. According to ICER’s health-benefit price benchmark, eculizumab would need to be priced between $13,200 – $19,400 to be […]

Atopic Dermatitis

Jul 2021 | Assessment

Interventions of Interest: abrocitinib (Cibinqo®, Pfizer) tralokinumab (Adtralza®, LEO Pharma) baricitinib (Olumiant®, Eli Lilly, Incyte Corporation) upadacitinib (Rinvoq®, AbbVie) ruxolitinib (Opzelura™, Incyte Corporation) Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of […]

Depression: Treatment-Resistant

Dec 2011 | Assessment

Interventions of interest, 2011 review: Repetitive transcranial magnetic stimulation, electroconvulsive therapy, vagus nerve stimulation, and cognitive-behavioral therapy/interpersonal therapy Major depressive disorder (MDD) is a common and debilitating condition; on an annual basis, it is estimated that nearly 14 million Americans will have at least one episode of MDD. While definitions of so-called “treatment-resistant” depression vary, this […]

Prostate Cancer

Dec 2008 | Assessment

Interventions of Interest: Brachytherapy and Proton beam therapy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas been focused […]